Evidence-based illicit drug policy: The potential contribution of economic evaluation techniques

Economist

Volumn 154, Issue 4, 2006, Pages 563-580

  Godfrey, Christine ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness; Evidence based policy; Illicit drug policy

Indexed keywords

DRUG USER; POLICY IMPLEMENTATION;

EID: 33845322969     PISSN: 0013063X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10645-006-9030-1     Document Type: Article

References (37)

1. Abou-Saleh, M. (2003), The Efficacy of Enhanced Counselling in the Primary Prevention of Hepatitis C Among Injecting Drug Users' Randomised Controlled Trial. Final report to the Department of Health, London, St George's Hospital Medical School.
2. Ades A.E., Sutton A.J. (2006). 'Multiparameter Evidence Synthesis in Epidemiology and Medical Decision-Making: Current Approaches,'. Journal of the Royal Statistical Society (Series A), 169:5-35
3. Becker G., Murphy K., Grossman M. (2006). 'The market for Illegal Goods: The Case of Drugs'. Journal of Political Economy, 114:38-60
4. Belenko S., Patapis N., French M. (2005) Economic Benefits of Drug Treatment: A Review of the Evidence Base for Policy Makers. Missouri, University of Pennsylvania, Treatment Research Unit
5. Blundell R., Costa Dias M. (2000). 'Evaluation Methods for Non-Experimental Data'. Fiscal Studies, 24:427-468
6. Buck D., Godfrey C., Sutton M. (1996) 'Economic and Other Views of Addiction: Implications for the Choice of Alcohol, Tobacco and drug policies'. Drug and Alcohol Review, 15:357-368
7. Caulkins J. (2005). 'Models Pertaining to Drug Policy Should Vary Over the Course of a Drug Epidemic'. In: Lingren B., Grossman M. (eds) Substance Use: Individual Behaviour, Social Interactions, Markets and Policies. Advances in Health Economics and Health Services Research, Vol. 16. Amsterdam, Elsevier
8. Caulkins, J.P., P. Rydell, S.S. Everingham, J. Chiesa and S. Bushway (1999), An ounce of Prevention, a Pound of Uncertainty: The Cost-Effectiveness of School-Based Drug Prevention Programs. Santa Monica, Drug Policy Research Center, RAND.
9. Culyer A.J. (1989). 'The Normative Economics of Health Care Finance and Provision'. Oxford Review of Economic Policy, 5:34-58
10. Department of Health (1996), Task Force to review Services for Drug Misusers, Report of an Independent Review of Drug Treatment Services. London, Department of Health.
11. Dijkgraaf M.G.W., van der Zanden B.P., de Borgie C.A.J.M., Blanken P., van Ree J.M., van den Brink W. (2005). 'Cost Utility Analysis of Co-Prescribed Heroin Compared with Methadone Maintenance Treatment in Heroin Addicts in two Randomised Trials'. British Medical Journal, 330:1297-1300
12. Doran C.M., Shanahan M., Bell J., Gibson A. (2004) 'A Cost-Effectiveness Analysis of Buprenorphine-Assisted Heroin Withdrawal'. Drug and Alcohol Review, 23:171-175
13. Drummond M.F., Sculpher M., Torrance G.W., O'Brien B.J., Stoddart G.L. (2005). Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford, Oxford Medical Publications
14. Godfrey, C., G. Eaton, C. McDougall and A. Culyer (2002), The Economic and Social Costs of Class A drug Use in England and Wales, 2000. Home Office Research Study 249, London: Home Office, http://www.homeoffice.gov.uk/rds/pdfs2/hors249.pdf
15. Godfrey C., Parrott S., Eaton G., Culyer C., McDougall C. (2005). 'Can we Model the Impact of Increased Treatment Expenditure on the UK Drug Market?'. In: Lindgren B., Grossman M. (eds) Substance Use: Individual Behaviour, Social Interactions, Markets and Policies. Advances in Health Economics and Health Services Research, Vol. 16. Amsterdam, Elsevier
16. Godfrey C., Stewart D., Gossop M. (2004) 'Economic Analysis of Costs and Consequences of the Treatment of Drug Misuse: 2 Year Outcome Data from the National Treatment Outcome Research Study (NTORS)'. Addiction, 99(6):697-707
17. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. (eds.) (1996). Cost-Effectiveness in Health and Medicine. New York, Oxford University Press
18. Gossop, M., J. Marsden and D. Stewart (1998), NTORS at One Year: Changes in Substance Use, Health and Criminal Behaviour One Year After Intake. London, Department of Health.
19. Griffith J.D., Hiller M.L., Knight K., Simpson D.D. (1996) 'A Cost-effectiveness Analysis of In-Prison Therapeutic Community Treatment and Risk Calculation'. The Prison Journal, 79:352-368
20. Hendry D. (1980). 'Econometrics - Alchemy or Science?'. Economica, 47:387-406
21. Hjelmgren J., Berggren F., Anderson F. (2001) 'Health Economic Guidelines - Similarities, Differences and Some Implications'. Value in Health, 4:225-250
22. Lee L.W. (1993) 'Would Harassing Drug Users Work?'. Journal of Political Economy, 101:939-959
23. Logan T.K., Hoyt W.H., McCollister K., French M.T., Leukefeld C., Minton L. (2004) 'Economic Evaluation of Drug Court: Methodology, Results and Policy Implications'. Evaluation and Program Planning, 27:381-396
24. Masson C.L., Barnett P.G., Sees K.L., Delucchi K.L., Rosen A., Wong W., Hall S.M. (2004) 'Cost and Cost-Effectiveness of Standard Methadone Maintenance Treatment Compared with Enriched 180-day Methadone Detoxification'. Addiction, 99:718-726
25. McCollister K.E., French M.T. (2004) 'The Relative Contribution of Outcome Domains in the Total Economic Benefit of Addiction Interventions: A Review of First Findings'. Addiction, 98:1647-1659
26. National Institute for Health and Clinical Excellence (NICE) (2004), Methods for Technology Appraisals, London, NICE.
27. National Institute for Health and Clinical Excellence (2006), Guidance for the Evaluation of Public Health Interventions. London, NICE.
28. Pacula R., MacCoun R., Reuter P., Chriqui J., Kilmer B., Harris K., Paoli L., Schafer C. (2005) 'What Does it Mean to Decriminalize Marijuana? A Cross-National Empirical Examination'. In: Lindgren B., Grossman M. (eds) Substance Use: Individual Behaviour, Social Interactions, Markets and Policies. Advances in Health Economics and Health Services Research, Vol. 16. Amsterdam, Elsevier
29. Reuter P. (2001). 'Why does Research have so Little Influence on American Drug Policy?'. Addiction, 96:373-376
30. Rydell, C. and S. Everingham (1994), Controlling Cocaine: Supply Versus Demand Programs. Santa Monica, CA, Drug Policy Research Center, RAND.
31. Sheerin I.G., Green F.T., Sellman J.D. (2004). 'What is the Cost-Effectiveness of Hepatitis C Treatment for Injecting Drug Users on Methadone Maintenance in New Zealand?'. Drug and Alcohol Review, 23:261-272
32. Sindelar J.L., Jofre-Bonet M., French M.T., McLellan A.T. (2004). 'Cost-Effectiveness Analysis of Addiction Treatment: Paradoxes of Multiple Outcomes'. Drug and Alcohol Dependence, 73:41-50
33. Svikis D.S., Golden A.S., Huggins G.R., Pickens R.W., McCaul M.E., Velez M.L., Rosendale C.T., Brooner R.K., Gazaway P.M., Stizer M.L., Ball C.E. (1997) 'Cost-Effectiveness of Treatment for Drug-Abusing Pregnant Women'. Drug and Alcohol Dependence, 45:105-113
34. UKATT Research Team (2005), 'Cost-effectiveness of Treatment for Alcohol Problems: Findings from the UK Alcohol Treatment Trial,' British Medical Journal, 331(7516), pp. 544-547.
35. UKCBTMM Project Group (2004), The Effectiveness and Cost Effectiveness of Cognitive Behaviour Therapy for Opiate Misusers in Methadone Maintenance Treatment: A Multicentre, Randomised, Controlled Trial. Final report to the Department of Health. London, St George's Hospital Medical School.
36. Zarkin G.A., Cates S.C., Bala M.V. (2000). 'Estimating the Willingness to Pay for Drug Abuse Treatments: A Pilot Study'. Journal of Substance Abuse Treatment, 18:409-418
37. Zarkin G.A., Dunlap L.J., Hick K.A., Mamo D. (2005) 'Benefits and Costs of Methadone Treatment: Results from a Lifetime Simulation Model'. Health Economics, 14:1133-1150